3.6.1.12	drug development	DCTPP1 counteracts the cytotoxic effect of the antitumoral demethylating agent decitabine (5-aza-deoxycytidine) by removing 5-aza-dCTP from the nucleotide pool and is being studied as a potential drug target to improve decitabine-based chemotherapy	756417	
3.6.1.12	drug development	the enzyme is a drug target	757391	
3.6.1.12	drug development	the enzyme is a factor involved in the mode of action of decitabine with potential value as enzymatic targets to improve decitabine-based chemotherapy	755999	
3.6.1.12	medicine	enzyme accumulates in the nucleus of cancer cells compared to the paired adjacent tissue cells in multiple carcinomas including lung, breast, liver, cervical, gastric and esophagus cancer. The higher expression in the nucleus of lung, gastric and esophagus cancer cells is associated with histological subtypes. The nucleic accumulation is apparently observed as well when tumor cell line MCF-7 is treated with H2O2 in vitro	733777